Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARG | P13631 | 14/20 | 0.57 |
| ▸ | RARB | P10826 | 13/20 | 0.57 |
| ▸ | RARA | P10276 | 11/20 | 0.57 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.53 |
| ▸ | RXRA | P19793 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL344714 | 0.90 | RARB (0.71) | RARGRARBRARAPDK2RXRA | |
| SCHEMBL5845709 | 0.88 | RARG (0.60) | RARGRARBRARAPDK2RXRA | |
| SCHEMBL5845951 | 0.87 | RARG (0.56) | RARGRARBRARAPDK2RXRA | |
| SCHEMBL5846075 | 0.86 | RARB (0.60) | RARGRARBRARAPDK2RXRA | |
| SCHEMBL5846741 | 0.86 | RARB (0.65) | RARGRARBRARAPDK2RXRA | |
| SCHEMBL6730351 | 0.86 | RARB (0.53) | RARGRARBRARAPDK2RXRA | |
| SCHEMBL2919935 | 0.85 | RARB (0.78) | RARGRARBRARARXRA | |
| SCHEMBL5846406 | 0.85 | RARG (0.55) | RARGRARBRARAPDK2RXRA | |
| SCHEMBL5846311 | 0.84 | RARG (0.56) | RARGRARBRARAPDK2RXRA | |
| SCHEMBL5846056 | 0.83 | RARB (0.59) | RARGRARBRARAPDK2RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7148245-B2 | Biphenyl derivatives substituted with an aromatic or heteroaromatic radical, and pharmaceutical and cosmetic compositions containing them | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-12-12 | — | — | US | disclosed |
| US-20040030141-A1 | Biphenyl derivatives substituted with an aromatic or heteroaromatic radical, and pharmaceutical and cosmetic compositions containing them | GALDERMA RESEARCH & DEVELOPMENT | 2004-02-12 | — | — | US | disclosed |
| US-6649612-B1 | Combating skin ageing and keratinization | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2003-11-18 | — | — | US | disclosed |
| US-6316009-B1 | FOR THERAPY OF DERMATOLOGICAL COMPLAINTS ASSOCIATED WITH A KERATINIZATION DISORDER, AND FOR COMBATING AGEING OF THE SKIN | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2001-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040030141-A1 | Biphenyl derivatives substituted with an aromatic or heteroaromatic radical, and pharmaceutical and cosmetic compositions containing them | AHR, TYR, CYP1A1 | RARG 39/4885RARB 26/4885RARA 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.